STOCK TITAN

FOXO TECHNOLOGIES - FOXO STOCK NEWS

Welcome to our dedicated page for FOXO TECHNOLOGIES news (Ticker: FOXO), a resource for investors and traders seeking the latest updates and insights on FOXO TECHNOLOGIES stock.

Company Overview

FOXO Technologies Inc is a technology platform company that integrates advanced epigenetic research, AI, and machine learning to transform longevity science for the life insurance industry. With a foundation rooted in innovative underwriting protocols and consumer engagement platforms, FOXO applies sophisticated DNA methylation analysis to identify molecular biomarkers of human health and aging. This approach not only modernizes the assessment of risk in the insurance sector but also expands the evaluation of overall wellness, positioning FOXO as a critical player in bridging technology with the scientific understanding of aging.

Business Segments

FOXO Technologies operates through two distinct but complementary business segments:

  • FOXO Labs: Focused on research and development, this segment leverages state-of-the-art machine learning algorithms and artificial intelligence to analyze epigenetic data, advancing our understanding of biological aging and current health status. The insights produced help drive improvements in underwriting protocols and risk assessment models within the life insurance industry.
  • FOXO Life: This segment translates scientific breakthroughs into practical applications, commercializing longevity science through enhanced life insurance products and services. By embedding epigenetic insights into consumer engagement platforms, FOXO Life enables tailored solutions that meet the evolving needs of policyholders and insurers alike.

Epigenetic Technology and Artificial Intelligence

The core of FOXO Technologies' operations is its integration of epigenetic technology with advanced AI methodologies. By analyzing changes in DNA methylation, FOXO identifies key biomarkers that reveal the current state of human health and aging. This process not only supports more accurate risk assessments for insurance underwriting but also offers an innovative perspective on the science of longevity. The application of machine learning enhances the precision of these models, ensuring that insights remain robust and relevant in dynamic market conditions.

Market Position and Competitive Landscape

Positioned at the intersection of technology and life sciences, FOXO Technologies stands out for its specialized focus on longevity science for the insurance market. Its detailed analysis of epigenetic data provides a significant edge in insurance underwriting, offering personalized insights that differentiate it from traditional assessment methods. The company maintains a competitive stance by continuously integrating technological advancements with rigorous scientific research, ensuring that its methodologies adhere to industry best practices and the highest standards of accuracy and reliability.

Strategic Initiatives and Acquisitions

FOXO’s strategic approach includes key acquisitions designed to complement its epigenetic technology and broaden its reach into connected health sectors such as community health and addiction recovery. These initiatives not only increase the diversity of its service offerings but are also structured to generate substantial cash flow, reinforcing the company’s overall financial robustness. The integration of these new business areas demonstrates FOXO's commitment to leveraging synergies that extend its technological capabilities beyond traditional life insurance, while reinforcing its role as a transformative force in the longevity science arena.

Operational Excellence and Value Proposition

FOXO Technologies emphasizes operational excellence by meticulously validating its AI-driven epigenetic models through extensive research and iterative testing. This diligence underpins a value proposition that is both scientifically rigorous and commercially viable. By harnessing detailed molecular insights and cutting-edge technological frameworks, FOXO provides a pathway for the accurate assessment of risk, which is invaluable for both insurers and the broader healthcare ecosystem.

Conclusion

In summary, FOXO Technologies Inc offers a comprehensive platform that combines robust epigenetic research with innovative AI methodologies to redefine the metrics of health and aging in the life insurance industry. Its dual-segment approach, centered around FOXO Labs and FOXO Life, not only refines insurance underwriting but also introduces transformative insights into longevity science. With a strategic focus on technological innovation and operational diligence, FOXO stands as a vital contributor to the evolving landscape of both life insurance and health technology.

Rhea-AI Summary

On June 14, 2024, FOXO Technologies announced two share exchange agreements with Rennova Health to acquire healthcare operations. The deals involve Myrtle Recovery Centers and Scott County Community Hospital (doing business as Big South Fork Medical Center). Myrtle Recovery Centers will be exchanged for $500,000 in FOXO common stock, while Scott County Community Hospital will be exchanged for $20 million in convertible preferred stock. These acquisitions are expected to generate significant cash flow for FOXO, with the acquired entities reporting $18.7 million in net revenue and $5.2 million in net income for 2023. The integration aims to leverage FOXO’s epigenetic technology in community health and addiction recovery, potentially expanding market reach and improving patient outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.92%
Tags
-
Rhea-AI Summary
FOXO Technologies Inc. received a Notice of Non-Compliance from NYSE for failing to file its Annual Report on Form 10-K by the due date. Despite challenges, the company is committed to regaining compliance, improving financial systems, and advancing transformative transactions to drive shareholder value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.1%
Tags
none
-
Rhea-AI Summary
FOXO Technologies Inc. announces a proposed merger with M2i Global, Inc. to focus on securing the nation's supply of critical materials and resources. The merger aims to develop a global value supply chain for critical minerals for the U.S. government and free trade partners, as well as create a strategic mineral reserve in partnership with the U.S. Federal Government. The collaboration brings together extensive experience, knowledge, and resources to drive value for shareholders and enhance operational efficiency.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.66%
Tags
Rhea-AI Summary
FOXO Technologies Inc. appoints Francis Colt deWolf to its Board of Directors, bringing over 20 years of experience in the financial services sector. The Company also received a notice of noncompliance from NYSE Regulation regarding its audit committee composition.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.75%
Tags
management
-
Rhea-AI Summary
FOXO Technologies Inc. (NYSE American: FOXO) has announced the formalization of its collaboration with KR8.ai Inc. and the exclusive license to KR8's AI-based software to support the development and commercial launch of its new health and wellness offering - the VITHAR™ AI Health Coach. The company aims to provide personalized health and wellness recommendations by leveraging epigenetic data, genetic insight, and growing patent estate with AI-driven analytic software and proprietary algorithms. The goal is to capture a meaningful share of the Health and Fitness App Market, which is projected to reach $35.7 billion by 2030, through a cost-effective go-to-market strategy. The new app will require users to send a saliva or blood sample, and the technology will combine this information with user health stats, as well as peer-reviewed clinical studies and other verified health resources to provide customized AI-driven health recommendations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.49%
Tags
AI
-
Rhea-AI Summary
FOXO Technologies Inc. (Ticker: FOXO) received a notice of noncompliance from NYSE Regulation due to the failure to timely file the Company’s Form 10-Q for the period ended September 30, 2023. The Company is committed to regaining compliance with the NYSE American’s continued listing requirements and has taken steps to enhance its financial infrastructure and ensure the highest standards of corporate governance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5%
Tags
none
Rhea-AI Summary
FOXO Technologies Inc. (NYSE American: FOXO) expects a reduction in losses of over $10 million for the third quarter of 2023 compared to the prior quarter. The company provided a business update on the planned commercial rollout of its new direct-to-consumer (DTC) app, the VITHAR™ AI Health Coach, and anticipates reporting financial results for the three and nine months ended September 30, 2023. The reduction in losses includes cash operational cost reductions in excess of $2.1 million over the second quarter of 2023. The company also plans to leverage social media influencers to enhance the commercial launch of the VITHAR AI Health Coach and expects annualized cost savings in excess of 52% for 2023, aiming to maintain a lean operating infrastructure to drive profitability following the commercial launch.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.82%
Tags
AI
-
Rhea-AI Summary
FOXO Technologies Inc. (NYSE American: FOXO) received a notice from NYSE Regulation stating that the Company is not in compliance with the continued listing standards of the NYSE American due to the delayed filing of its Quarterly Report on Form 10-Q for the quarter ended September 30, 2023. The Company has a six-month initial cure period to file the Form 10-Q with the SEC, with the possibility of an additional six-month cure period if needed.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.72%
Tags
none
-
Rhea-AI Summary
FOXO Technologies Inc. (NYSE American: FOXO) announces a webinar to unveil its new direct-to-consumer app, the VITHAR™ AI Health Coach, designed to combine health and epigenetic data for actionable insights and coaching.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.04%
Tags
AI
Rhea-AI Summary
FOXO Technologies Inc. (NYSE American: FOXO) announced a webinar on November 10, 2023, to introduce its new direct-to-consumer (DTC) app, the VITHAR™ AI Health Coach, which will leverage epigenetic data and algorithms to provide personalized health insights and coaching. The app aims to improve user's overall health and longevity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.87%
Tags
AI

FAQ

What is the current stock price of FOXO TECHNOLOGIES (FOXO)?

The current stock price of FOXO TECHNOLOGIES (FOXO) is $0.1126 as of April 7, 2025.

What is the market cap of FOXO TECHNOLOGIES (FOXO)?

The market cap of FOXO TECHNOLOGIES (FOXO) is approximately 3.1M.

What is the main focus of FOXO Technologies?

FOXO Technologies specializes in commercializing longevity science by integrating epigenetic technology with advanced AI and machine learning to enhance underwriting protocols for the life insurance industry.

What are the primary business segments of FOXO Technologies?

The company operates through two key segments: FOXO Labs, which drives research and technological development, and FOXO Life, which commercializes these insights through enhanced insurance products and services.

How does FOXO Technologies utilize epigenetic data?

The company applies sophisticated DNA methylation analysis to identify biomarkers of health and aging, thereby refining risk assessments and underwriting processes in the life insurance market.

How does FOXO differentiate itself from competitors?

By merging robust epigenetic research with cutting-edge AI and machine learning tools, FOXO offers a scientifically rigorous and technologically advanced approach to assessing human health and risk, setting it apart in the industry.

Who are the primary customers of FOXO Technologies?

FOXO primarily serves the life insurance sector, working with insurers and underwriters, while also exploring applications in broader health technology and community wellness initiatives.

What strategic initiatives support FOXO's business model?

The company has pursued strategic acquisitions that complement its core epigenetic capabilities, expanding its reach into areas such as community health and addiction recovery, which reinforce its innovative platform.

What technological innovations are central to FOXO's operations?

FOXO Technologies employs advanced AI, machine learning, and epigenetic biomarker analysis to produce precise insights on aging and health, enabling enhanced risk assessment and underwriting models.

How does FOXO ensure the reliability of its solutions?

By adhering to stringent scientific methodologies and continuous technological refinement, FOXO validates its AI-driven models and epigenetic testing processes, ensuring that its solutions remain accurate and industry compliant.
FOXO TECHNOLOGIES

NYSE:FOXO

FOXO Rankings

FOXO Stock Data

3.06M
21.24M
9.9%
2.69%
8%
Health Information Services
Services-commercial Physical & Biological Research
Link
United States
MINNEAPOLIS